Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

rocapuldencel-T

- PMLiVE

AstraZeneca rejects ‘final offer’ from Pfizer

And US pharma company rules out hostile takeover

Bristol-Myers Squibb (BMS) building

BMS’ nivolumab gets breakthrough status

But shares fall on concerns over new trial data

- PMLiVE

Macmillan campaign for legacy donations

Cancer charity aims to raise awareness of the importance of gifts in wills

- PMLiVE

MPs grill Read over Pfizer’s commitments to UK

CEO faces combative parliamentary hearing over AstraZeneca bid

GW hires Pfizer’s Kenneth Sommerville

Appointed VP clinical research at company specialising in cannabinoids

- PMLiVE

AZ circles wagons as Pfizer hints at hostile takeover

Aims for annual revenues of $45bn by 2023

- PMLiVE

Pfizer faces opposition to AZ takeover as Q1 figures disappoint

Labour leader Ed Miliband calls for public inquiry into deal

- PMLiVE

UPDATE: AZ rejects improved Pfizer bid

Continues to assert independence as Pfizer appeals to Prime Minister David Cameron

- PMLiVE

Pfizer confirms interest in AstraZeneca megamerger

Says it has twice tried to engage in merger talks with big pharma rival

- PMLiVE

NICE rejects Roche’s Kadcyla as “unaffordable”

Cancer drug unable to justify £90,000 price tag

- PMLiVE

Pfizer set to file Xeljanz for psoriasis

Set to add another indication after positive study results

- PMLiVE

Pfizer rumoured to be after AstraZeneca

Is this the return of the pharma mega-merger?

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links